The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

Eur J Gynaecol Oncol. 2000;21(1):84-5.

Abstract

A phase I study was performed in order to evaluate the tolerability of the combination of fixed doses of carboplatin and paclitaxel and escalated doses of topotecan as first line chemotherapy for advanced epithelial ovarian cancer. Three stage III and one stage IV patients entered the study. The dose limiting toxicity (neutropenia and thrombocytopenia) was reached at the first dose level: paclitaxel 175 mg/m2 on day 1, carboplatin AUC 5 on day I and topotecan 0.5 mg/m2 daily from day 1 to day 3. We conclude that it is not possible to add topotecan to standard regimens of carboplatin and paclitaxel without bone marrow support.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Dose-Response Relationship, Drug
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Middle Aged
  • Neutropenia / chemically induced
  • Neutropenia / prevention & control
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / therapy
  • Paclitaxel / administration & dosage
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / prevention & control
  • Topotecan / administration & dosage

Substances

  • Topotecan
  • Carboplatin
  • Paclitaxel